Osborne Clarke advises neuroClues® on €10 million Series A fundraising to bring AI powered neurological biomarkers across Europe and prepare U.S. entry

International legal practice Osborne Clarke has advised on the Series A investment in neuroClues®, European MedTech company powered by P3Lab SRL and developing AI-powered neurological biomarkers from eye movements. The round, led by Teampact Ventures, White Fund and the EIC Fund (European Innovation Council), with participation from existing shareholders InvestBW, Leansquare and Wallonie Entreprendre, and the support of Olivier Legrain, Chairman of the Board and CEO of IBA, brings the total capital raised by neuroClues to EUR 25 million, including additional non-dilutive funding secured concurrently.

Founded in 2020 by Antoine Pouppez, Pierre Daye and Pierre Pouget (CNRS director at Paris Brain Institute), neuroClues, powered by P3Lab, develops and commercializes a compact, non-invasive, CE-marked (Class IIa) medical device that records and analyses eye movements to extract objective and reproducible neurological biomarkers in minutes. The company obtained its CE certification in January 2025 and within months, over 30 devices were deployed across France, Belgium, Italy, Germany, Switzerland, the Netherlands and the United Kingdom, in university hospitals, private neurology practices and research centers. neuroClues supports clinicians in assessing neurological anomalies objectively, leading to faster and more accurate diagnoses of neurodegenerative diseases such as Parkinson's and Alzheimer's.

The team in Brussels was led by Corporate partner Hadrien Chef and Counsel Laurent De Pauw and included Partner Olivier Lambillon, Senior Associate Shahine Kalantari, Associate Mathilde Drion and Associate Mathieu Lambeau.

Osborne Clarke's corporate team is considered a go-to practice for life sciences and healthcare companies, working with leading global businesses, fast-growth start-ups and market challengers. The team advises on all stages of company development across all corporate issues, from equity and debt fundraisings to M&A, IPOs and JVs.